Clinical Trials Logo

Overweight clinical trials

View clinical trials related to Overweight.

Filter by:

NCT ID: NCT05824039 Completed - Obesity Clinical Trials

Safety and Efficacy of Medicinal Plant Extract in Overweight and Obese Participants.

Start date: March 20, 2021
Phase: N/A
Study type: Interventional

The purpose of this randomized , double -blind clinical trial is to evaluate the efficacy and safety of a daily administration of Nitraria retusa extract in overweight and obese participants, during 10 days.

NCT ID: NCT05822830 Active, not recruiting - Obesity Clinical Trials

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

SURMOUNT-5
Start date: April 21, 2023
Phase: Phase 3
Study type: Interventional

The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2 Diabetes. The study will last around 74 weeks.

NCT ID: NCT05822167 Completed - Obesity, Overweight Clinical Trials

Effect of Food Temperature and Diet Composition on Satiety, Satiety Hormones, Chewing Time and Neuronal Activity

Start date: April 20, 2023
Phase: N/A
Study type: Interventional

Obesity and its related illnesses have become serious health issues, obesity is today the fifth most common cause of death. Obesity rate has dramatically enhanced in both male and female, and across all ages. Food and energy intake during habitual meals, energy balance, energy expended during physical activity, all play an important role in management of weight. Lifestyle changes and nutritional strategies are emerging as the best line of treatment for obesity. The achievement of satiety along with, the reduction in dietary intake is the primary goal of nutritionists and food scientists. Appetite control can be defined by two terms; satiety and satiation. The interaction between appetite, food intake, and hormones secreted by the gastrointestinal tract, which are secreted in response to macronutrients like carbohydrates, fats and proteins are the satiety regulators. The gut hormones including glucagon like peptide 1(GLP1), cholecystokinin (CCK) are anorexigenic in action, cause slowing of meal digestion and reduce food intake thus inducing satiation and satiety. The CCK hormone plays a key role in delaying of stomach emptying by fundus relaxation and antral inhibition, ultimately causing major satiation. The incretin hormone GLP-1's main action is to stimulate insulin secretion, inhibit glucagon secretion, regulating postprandial glucose and provide negative feedback to the stomach thereby controlling appetite. Research is needed in meal properties and different diets which may affect gut-brain signaling and altering the mechanisms of gut hormonal secretion, thus further influencing appetite satiation and satiety scores. This knowledge can be utilized in energy expenditure and weight management. Serving temperatures alter perceived intensities, flavor and acceptances of food as well. Brain areas work in close association with the thermal perception and emotions. In neuroimaging studies neural changes have been when body is exposed to different temperatures either environmental or oral cavity. Temperature of food play an important role in the palatability and affective value of food and, consequently, in appetite regulation. Limited research has been done so far how food temperature is related to sensory perception and satiety Chewing and food texture also affect satiety and satiation. The oral processing, eating rate and physical forms of food i.e., solid versus liquid or semi-solid are all physiologically related to satiety and an individual's behavior to understand this oral sensory satiety effect, requires further studies. The number of chews has been studied showing an association between reduction in food intake with increasing number of chews. EEG is a noninvasive neuroimaging technique, helping in evaluating the cognitive part of food stimuli and food ingestion in relation to gut hormones. Sensory properties of previously identified as drivers of refreshing perception, enhance alpha and beta brain oscillations as observed in prior EEG studies. Many factors influence satiety including food composition, temperature, environment, last meal and preload. Limited literature is available about temperature of food and its influence on satiety. My study aims to find 1) the effect of temperature of high carbohydrate, high fat meal and high protein meal on the satiety scores, satiety-related hormones, EEG and EMG. 2. To find the effect of chewing time of food on the satiety scores, satiety- related hormones, EEG and EMG.

NCT ID: NCT05820737 Recruiting - Clinical trials for Gastrointestinal Dysfunction

A Study to Assess the Gut Health Effects of Heat-killed Post-biotics in Overweight and Obese Adults

Start date: April 14, 2024
Phase: N/A
Study type: Interventional

The present study is a randomized, double-blind (Double dummy), placebo-controlled, parallel-group study to assess the gut health effects of heat-killed post biotics in overweight and obese individuals

NCT ID: NCT05817487 Completed - Vascular Diseases Clinical Trials

Effects of COP Exercise and HIIT on Vascular Health in Young Overweight Females

Start date: February 18, 2019
Phase: N/A
Study type: Interventional

The goal of this study is to determine the effects of high-intensity interval training and crossover point exercise training on vascular health in young overweight women.

NCT ID: NCT05815680 Completed - Overweight Subjects Clinical Trials

A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects

Start date: April 6, 2023
Phase: Phase 1
Study type: Interventional

This trial is conducted in China. The aim of the trial is to investigate the influence of IBI362 on pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of warfarin, metformin, warfarin, atorvastatin, digoxin in overweight or obese subjects.

NCT ID: NCT05814107 Recruiting - Type 2 Diabetes Clinical Trials

Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus

Start date: May 9, 2023
Phase: Phase 1
Study type: Interventional

A study designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of CT-996 in overweight/obese participants and participants with T2DM.

NCT ID: NCT05813925 Recruiting - Clinical trials for Obesity or Overweight

A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight

Start date: April 3, 2023
Phase: Phase 3
Study type: Interventional

This study will look at how well the new medicine CagriSema helps people with excess body weight lose weight compared to another medicine, semaglutide. The participants will receive one injection once a week. The study medicine will be injected with a thin needle, typically in the stomach, thighs or upper arms. The study will last for about 1½ years.

NCT ID: NCT05813795 Active, not recruiting - Weight Management Clinical Trials

A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity

Start date: April 5, 2023
Phase: Phase 3
Study type: Interventional

The aim of the study is to evaluate the efficacy and safety of XW003 versus placebo in adults with overweight or obesity

NCT ID: NCT05811702 Recruiting - Healthy Clinical Trials

The Impact of High-Fat Ketogenic Diet and Low-Fat Diet in Women Body Weight

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

The aim of this study is investigated the effect of high fat Ketogenic Diet (HFKD) in weight reduction compared to the low-fat diet (LFD) among Saudi overweight and obese women. A randomized acute controlled trial of twenty-eight healthy overweight or obese women in Saudi Arabia, aged between 18 and 40 with a body mass index between 25 and 34.5 kg m2 and fat parentage above 30% . The participants have followed ether HFKD or LFD for 12 weeks.